Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1995 3
1998 1
2000 2
2002 1
2003 2
2006 1
2008 2
2009 1
2011 1
2012 2
2016 1
2017 2
2018 4
2019 3
2020 2
2021 6
2022 1
2023 4
2024 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, Sandhu I, Ganly P, Baker BW, Jackson SR, Stoppa AM, Simpson DR, Gimsing P, Palumbo A, Garderet L, Cavo M, Kumar S, Touzeau C, Buadi FK, Laubach JP, Berg DT, Lin J, Di Bacco A, Hui AM, van de Velde H, Richardson PG; TOURMALINE-MM1 Study Group. Moreau P, et al. N Engl J Med. 2016 Apr 28;374(17):1621-34. doi: 10.1056/NEJMoa1516282. N Engl J Med. 2016. PMID: 27119237 Free article. Clinical Trial.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.
Goldschmidt H, Mai EK, Bertsch U, Fenk R, Nievergall E, Tichy D, Besemer B, Dürig J, Schroers R, von Metzler I, Hänel M, Mann C, Asemissen AM, Heilmeier B, Weinhold N, Huhn S, Kriegsmann K, Luntz SP, Holderried TAW, Trautmann-Grill K, Gezer D, Klaiber-Hakimi M, Müller M, Khandanpour C, Knauf W, Scheid C, Munder M, Geer T, Riesenberg H, Thomalla J, Hoffmann M, Raab MS, Salwender HJ, Weisel KC; German-Speaking Myeloma Multicenter Group (GMMG) HD7 investigators. Goldschmidt H, et al. Among authors: salwender hj. Lancet Haematol. 2022 Nov;9(11):e810-e821. doi: 10.1016/S2352-3026(22)00263-0. Lancet Haematol. 2022. PMID: 36328040 Clinical Trial.
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial.
Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R, Rajkumar SV; TOURMALINE-MM3 study group. Dimopoulos MA, et al. Lancet. 2019 Jan 19;393(10168):253-264. doi: 10.1016/S0140-6736(18)33003-4. Epub 2018 Dec 10. Lancet. 2019. PMID: 30545780 Clinical Trial.
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients.
Mai EK, Hielscher T, Bertsch U, Salwender HJ, Zweegman S, Raab MS, Munder M, Pantani L, Mancuso K, Brossart P, Beksac M, Blau IW, Dürig J, Besemer B, Fenk R, Reimer P, van der Holt B, Hänel M, von Metzler I, Graeven U, Müller-Tidow C, Boccadoro M, Scheid C, Dimopoulos MA, Hillengass J, Weisel KC, Cavo M, Sonneveld P, Goldschmidt H. Mai EK, et al. Among authors: salwender hj. Leukemia. 2024 Mar;38(3):640-647. doi: 10.1038/s41375-023-02105-6. Epub 2023 Dec 7. Leukemia. 2024. PMID: 38062124 Free PMC article. Clinical Trial.
CD8+ CD28- regulatory T cells after induction therapy predict progression-free survival in myeloma patients: results from the GMMG-HD6 multicenter phase III study.
Kriegsmann K, Ton GNHQ, Awwad MHS, Benner A, Bertsch U, Besemer B, Hänel M, Fenk R, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Seidel-Glätzer A, Weisel KC, Salwender HJ, Müller-Tidow C, Raab MS, Goldschmidt H, Mai EK, Hundemer M. Kriegsmann K, et al. Among authors: salwender hj. Leukemia. 2024 Jul;38(7):1621-1625. doi: 10.1038/s41375-024-02290-y. Epub 2024 Jun 3. Leukemia. 2024. PMID: 38830959 Free PMC article. Clinical Trial. No abstract available.
Selective elimination of immunosuppressive T cells in patients with multiple myeloma.
Awwad MHS, Mahmoud A, Bruns H, Echchannaoui H, Kriegsmann K, Lutz R, Raab MS, Bertsch U, Munder M, Jauch A, Weisel K, Maier B, Weinhold N, Salwender HJ, Eckstein V, Hänel M, Fenk R, Dürig J, Brors B, Benner A, Müller-Tidow C, Goldschmidt H, Hundemer M. Awwad MHS, et al. Among authors: salwender hj. Leukemia. 2021 Sep;35(9):2602-2615. doi: 10.1038/s41375-021-01172-x. Epub 2021 Feb 17. Leukemia. 2021. PMID: 33597728 Free PMC article.
Measurable Residual Disease Monitoring in AML With FLT3-ITD Treated With Intensive Chemotherapy Plus Midostaurin.
Rücker FG, Bullinger L, Cocciardi S, Skambraks S, Luck TJ, Weber D, Krzykalla J, Pozek E, Schneider IJ, Corbacioglu A, Gaidzik VI, Meid A Dr, Aicher S, Stegelmann F, Schrade A, Theis F, Fiedler W, Salih HR, Wulf GG, Salwender HJ, Schroeder T, Götze KS, Kühn MWM, Lübbert M, Schlenk RF, Benner A, Thol FR, Heuser M, Ganser A, Döhner H, Döhner K. Rücker FG, et al. Among authors: salwender hj. Blood Adv. 2024 Sep 30:bloodadvances.2024013758. doi: 10.1182/bloodadvances.2024013758. Online ahead of print. Blood Adv. 2024. PMID: 39348668
Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
Mai EK, Goldschmid H, Miah K, Bertsch U, Besemer B, Hänel M, Krzykalla J, Fenk R, Schlenzka J, Munder M, Dürig J, Blau IW, Huhn S, Hose D, Jauch A, Kunz C, Mann C, Weinhold N, Scheid C, Schroers R, von Metzler I, Schieferdecker A, Thomalla J, Reimer P, Mahlberg R, Graeven U, Kremers S, Martens UM, Kunz C, Hensel M, Benner A, Seidel-Glätzer A, Weisel KC, Raab MS, Salwender HJ; German-speaking Myeloma Multicenter Group (GMMG) HD6 investigators. Mai EK, et al. Among authors: salwender hj. Lancet Haematol. 2024 Feb;11(2):e101-e113. doi: 10.1016/S2352-3026(23)00366-6. Lancet Haematol. 2024. PMID: 38302221 Free article. Clinical Trial.
Implications and prognostic impact of mass spectrometry in patients with newly-diagnosed multiple myeloma.
Mai EK, Huhn S, Miah K, Poos AM, Scheid C, Weisel KC, Bertsch U, Munder M, Berlanga O, Hose D, Seckinger A, Jauch A, Blau IW, Hänel M, Salwender HJ, Benner A, Raab MS, Goldschmidt H, Weinhold N. Mai EK, et al. Among authors: salwender hj. Blood Cancer J. 2023 Jan 4;13(1):1. doi: 10.1038/s41408-022-00772-9. Blood Cancer J. 2023. PMID: 36599831 Free PMC article. Clinical Trial.
Treatment of chemotherapy-induced emesis.
Egerer G, Hegenbart U, Salwender HJ, Goldschmidt H, Ho AD. Egerer G, et al. Among authors: salwender hj. Antibiot Chemother (1971). 2000;50:171-83. doi: 10.1159/000059326. Antibiot Chemother (1971). 2000. PMID: 10874465 Review. No abstract available.
40 results